<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE collection SYSTEM "BioC.dtd">
<collection><source>PMC</source><date>20201214</date><key>pmc.key</key><document><id>37310</id><infon key="license">NO-CC CODE</infon><passage><infon key="article-id_doi">10.1186/1471-2350-2-8</infon><infon key="article-id_pmc">37310</infon><infon key="article-id_pmid">11495633</infon><infon key="article-id_publisher-id">1471-2350-2-8</infon><infon key="fpage">8</infon><infon key="journal-title">BMC Medical Genetics</infon><infon key="lpage">8</infon><infon key="name_0">surname:Shcherbak;given-names:Natalia S</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="volume">2</infon><infon key="year">2001</infon><offset>0</offset><text>Apolipoprotein E gene polymorphism is not a strong risk factor for diabetic nephropathy and retinopathy in Type I diabetes: case-control study</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>143</offset><text>Background</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>154</offset><text>The gene encoding apolipoprotein E (APOE) has been proposed as a candidate gene for vascular complications in Type I diabetes. This study aimed to investigate the influence of three-allelic variations in the APOE gene for the development of diabetic retinopathy and nephropathy.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>433</offset><text>Results</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>441</offset><text>Neither APOE alleles frequencies or APOE genotypes frequencies differed between Type I diabetic groups either with or without nephropathy. Similar results were found for patients with and without diabetic retinopathy.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>659</offset><text>Conclusions</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>671</offset><text>APOE gene polymorphism does not determine genetic susceptibility for the development of diabetic retinopathy in Type I diabetes patients. Association between APOE gene polymorphism and diabetic nephropathy may be weak or moderate, but not strong.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>918</offset><text>Background</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>929</offset><text>Familial and epidemiological studies have indicated that there is a strong genetic component in the aetiology of diabetic nephropathy in Type I diabetes patients. Apolipoprotein E (apoE) was discovered as a plasma protein involved in the metabolism of lipoproteins. Recently, the apolipoprotein E (APOE) gene has been suggested to be a risk factor for the development of micro- and macrovascular complications in diabetic patients.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1361</offset><text>The APOE gene is polymorphic. There are three common alleles, E2, E3, and E4, which code for three major isoforms, resulting in six common genotypes. Individuals with apoE2 have higher triglyceride levels and are associated with lower cholesterol compared to individuals with apoE3. Individuals with apoE4 often have elevated plasma cholesterol levels. There is an increased prevalence of cardiovascular disease and particularly Alzheimer's disease.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1811</offset><text>Apolipoprotein E polymorphism may influence the metabolism of lipoproteins in diabetic patients. Several recent studies have suggested that this polymorphism may be associated with a genetic predisposition for diabetic nephropathy. Thus, APOE is an important candidate gene for the development of microvascular complications in Type I diabetes patients.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2165</offset><text>The aim of this study was to investigate the influence of APOE gene polymorphism in the development of diabetic nephropathy and retinopathy in Type I diabetes patients.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>2334</offset><text>Materials and Methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>2356</offset><text>Patients</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>2365</offset><text>In this study, all patients were Russians with unrelated Type I diabetes. All diabetic patients for the case-control study were recruited from St.Petersburg Diabetological Centres and had participated in the program &quot;Diabetes mellitus&quot; (which included monitoring of trends and examinations of the determinants of vascular complications in Type I diabetes) carried out in St. Petersburg, Russia since 1997.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>2771</offset><text>The diabetic patients included in this study satisfied the World Health Organization criteria for diabetes mellitus. Glycated haemoglobin (HbAlc) was measured by ion exchange chromatography. At entry the patients had HbAlc levels of 5.7 to 16.8%.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>3018</offset><text>The Type I diabetes groups consisted of 74 subjects with nephropathy and 92 subjects without. The study covered 76 Type I diabetes patients with diabetic retinopathy and 96 patients without. Some subjects had more than one type of diabetic complication, and consequently were analysed in more than one group.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>3327</offset><text>For Type I diabetes patients, all the information was examined for evidence of nondiabetic renal disease. Then questionnaires, medical records, and measurements of albumin excretion were used to determine whether they had diabetic nephropathy. Those patients were considered to have diabetic nephropathy if they were receiving treatment for renal disease and either suffered from persisting proteinuria, or had persisting high albuminuria. Urinary albumin excretion was measured by nephelometry. Nephropathy was defined as a persistent urinary albumin excretion of more than 20 μg/min, or 30 mg/24 h in two out of three consecutive urinalyses. Individuals with no history of nephropathy and no albumin excretion were considered free of nephropathy.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>4077</offset><text>Fundus ophthalmoscopy and angiofluorography were used to diagnose retinopathy. The diabetic retinopathy group consisted of those showing retinal change, while Type I diabetes control group were those who showed no signs of retinopathy.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>4313</offset><text>DNA genotyping</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>4328</offset><text>Blood was collected from each individual and stored in ethylenediaminetetraacetic acid (EDTA) tubes at -20°C. Genomic DNA was obtained from lysed white blood cells by phenol-chloroform extraction. The APOE gene polymorphism was detected by polymerase chain reaction (PCR). APOE genotyping was performed by the method of Hixson and Vernier using a modified version described by Skobeleva et al..</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>4724</offset><text>The sequence of the sense oligonucleotide primer was 5'-AGATGCGGGCACGGCTGTTCAAGGA-3', and the antisense primer was 5'-CCCTCGCGAGCCCCGGCCTGGTACAC-3'. Each amplification reaction contained 50 mM KCl, 10 mM tris-HCl pH 8.4, 1.5 mM MgCl2, 0.25 μM of each primer, 200 μM dNTP, 10% DMSO, 0.1 μg DNA and 1 U Tag polymerase in a final volume of 20 μl. After denaturation step at 95°C for 5 minutes followed by 30 cycle of denaturation at 92°C (1 min), annealing at 64°C (1 min), extension at 72°C (1.5 min) and a final extension at 72°C (5 min) using a MiniCycler (MJ Research, Watertown, MA, USA). Genotypes were determined by Hin61 (Fermentas, Vilnius, Lithuania) digestion of a 244-base pair PCR-amplified fragment spanning the two polymorphic sites. The digested DNA fragments were separated using migration on 12% polyacrylamide gels and visualized under UV illumination after ethidium bromide staining. The codominant alleles E2, E3, and E4 determine the six APOE genotypes.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>5706</offset><text>Statistical testing</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5726</offset><text>All data are presented as means ± SD. Groups were compared using the Student's t test for comparison of two groups for quantitative variables. Allele frequency among control subjects and case subjects were compared using standard Χ2 tests. The difference in genotype frequencies between the groups was tested by Fisher's exact test. A value of P &lt; 0.05 was considered significant.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>6110</offset><text>Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>6118</offset><text>Clinical characteristics by study group are shown in Table 1. No significant difference was seen between groups with vascular complications (nephropathy and retinopathy) and those without, no matter the age, diabetes duration, age at diabetes onset, and mean HbAlc.</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>6384</offset><text>Clinical characteristics by study groups</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;Type I diabetes&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;Type I diabetes&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;Type I diabetes&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;Type I diabetes&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;subjects&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;subjects&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;subjects&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;subjects&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;with&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;without&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;with&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;without&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;nephropathy&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;nephropathy&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;retinopathy&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;retinopathy&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;(DN+)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(DN-)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(DR+)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(DR-)&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;Total subjects&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;74&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;92&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;76&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;96&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;Age (years)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;25.1 ± 11.9&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;20.8 ± 8.7&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;29.8 ± 10.1&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;22.9 ± 9.1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;Sex&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;(male/female)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;40/34&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;40/52&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;34/42&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;50/46&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;Diabetes&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;duration&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;14.8 ± 8.8&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;10.9 ± 4.3&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;17.4 ± 8.6&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;11.2 ± 3.1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;(years)&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;Diabetes onset&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;(years)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;11.1 ± 6.2&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;10.3 ± 6.8&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;12.2 ± 8.1&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;11.5 ± 5.2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;HbA1c(%)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;10.5 ± 2.2&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;9.8 ± 1.9&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;10.6 ± 1.7&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;9.9 ± 1.7&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>6425</offset><text>	Type I diabetes	Type I diabetes	Type I diabetes	Type I diabetes	 		subjects	subjects	subjects	subjects	 		with	without	with	without	 		nephropathy	nephropathy	retinopathy	retinopathy	 		(DN+)	(DN-)	(DR+)	(DR-)	 	Total subjects	74	92	76	96	 	Age (years)	25.1 ± 11.9	20.8 ± 8.7	29.8 ± 10.1	22.9 ± 9.1	 	Sex					 	(male/female)	40/34	40/52	34/42	50/46	 	Diabetes					 	duration	14.8 ± 8.8	10.9 ± 4.3	17.4 ± 8.6	11.2 ± 3.1	 	(years)					 	Diabetes onset					 	(years)	11.1 ± 6.2	10.3 ± 6.8	12.2 ± 8.1	11.5 ± 5.2	 	HbA1c(%)	10.5 ± 2.2	9.8 ± 1.9	10.6 ± 1.7	9.9 ± 1.7	 	</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>7006</offset><text>Data are means ± SD</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>7027</offset><text>The frequency of each genotype in each group conformed to the Hardy -Weinberg equilibrium.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>7118</offset><text>The distribution of the APOE genotypes is shown in Table 2. There was no significant difference in APOE genotype and allele frequency between nephropathic and normoalbuminuric diabetic patients. In this study, no association was found between diabetic retinopathy and APOE polymorphisms. APOE allele frequencies for males and females were similar within groups and in different groups.</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>7504</offset><text>Distributionof APOE genotypes and alleles in the case-control association study</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;Type I&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;Type I&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;P&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;Type I&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;Type I&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;P&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;diabetes&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;diabetes&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;value&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;diabetes&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;diabetes&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;Value&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;subjects&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;subjects&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;subjects&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;subjects&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;with&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;without&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;with&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;without&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;nephropathy&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;nephropathy&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;retinopathy&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;retinopathy&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;(DN+)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(DN-)&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;(DR+)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(DR-)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;n (%)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;n (%)&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;n (%)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;n (%)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;m/f (%/%)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;m/f (%/%)&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;m/f (%/%)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;m/f (%/%)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;74 (100)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;92(100)&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;76 (100)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;96(100)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;Total subjects&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;40/34&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;40/52&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;34/42&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;50/46&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;(54.0/46.0)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(43.5/56.5)&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;(44.7/55.3)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(52.1/47.9)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;7&quot;&gt;&lt;hr/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;2(2.2)&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;1(1.0)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;&lt;italic&gt;E2E2&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0/2&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;NS&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0/1&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;NS&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;(0/3.8)&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;(0/2.2)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;48(64.9)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;54(58.7)&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;45(59.2)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;61(63.6)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;&lt;italic&gt;E3E3&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;25/23&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;27/27&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;NS&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;21/24&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;33/28&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;NS&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;(62.5/67.6)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(67.5/51.9)&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;(61.8/57.1)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(66.9/60.9)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;1(1.0)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;&lt;italic&gt;E4E4&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;NS&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0/1&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;NS&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;(0/2.2)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;13(17.6)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;20(21.7)&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;18(23.7)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;16(16.7)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;&lt;italic&gt;E2E3&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;8/5&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;5/15&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;NS&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;9/9&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;6/10&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;NS&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;(20.0/14.7)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(12.5/28.8)&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;(26.4/21.4)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(12.0/21.7)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;3(4.0)&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;3(3.9)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1(1.0)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;&lt;italic&gt;E2E4&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0/3&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;NS&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0/3&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1/0&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;NS&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;(0/8.9)&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;(0/7.2)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(2.0/0)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;10(13.5)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;16(17.4)&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;10(13.2)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;16(16.7)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;&lt;italic&gt;E3E4&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;7/3&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;8/8&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;NS&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4/6&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;10/6&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;NS&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;(17.5/8.8)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(20.0/15.5)&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;(11.8/14.3)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(20.0/13.0)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;16(10.8)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;24(13.0)&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;21(13.8)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;19(9.9)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;&lt;italic&gt;E2&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;8/8&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;5/19&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;NS&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;9/12&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;7/12&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;NS&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;(10.0/11.8)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(6.3/18.3)&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;(13.2/14/3)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(7.0/13.0)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;119(80.4)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;144(78.3)&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;118(77.6)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;154(80.2)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;&lt;italic&gt;E3&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;65/54&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;67/77&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;NS&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;55/63&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;82/72&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;NS&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;(81.3/79.4)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(83.7/74.0)&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;(80.9/75.0)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(82.0/78.3)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;13(8.8)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;16(8.7)&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;13(8.6)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;19(9.9)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;&lt;italic&gt;E4&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;7/6&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;8/8&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;NS&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4/9&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;11/8&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;NS&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;(8.7/8.8)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(10.0/7.7)&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;(5.9/10.7)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(11.0/8.7)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;7&quot;&gt;&lt;hr/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;Total&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;148 (100)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;184(100)&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;152(100)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;192(100)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;chromosomes&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;80/68&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;40/104&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;68/84&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;100/92&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;(54.1/45.9)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(43.5/56.5)&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;(44.7/55.3)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(52.1/47.9)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>7584</offset><text>	Type I	Type I	P	Type I	Type I	P	 		diabetes	diabetes	value	diabetes	diabetes	Value	 		subjects	subjects		subjects	subjects		 		with	without		with	without		 		nephropathy	nephropathy		retinopathy	retinopathy		 		(DN+)	(DN-)		(DR+)	(DR-)		 		n (%)	n (%)		n (%)	n (%)		 		m/f (%/%)	m/f (%/%)		m/f (%/%)	m/f (%/%)		 		74 (100)	92(100)		76 (100)	96(100)		 	Total subjects	40/34	40/52		34/42	50/46		 		(54.0/46.0)	(43.5/56.5)		(44.7/55.3)	(52.1/47.9)		 		 			2(2.2)			1(1.0)		 	E2E2	0	0/2	NS	0	0/1	NS	 			(0/3.8)			(0/2.2)		 		48(64.9)	54(58.7)		45(59.2)	61(63.6)		 	E3E3	25/23	27/27	NS	21/24	33/28	NS	 		(62.5/67.6)	(67.5/51.9)		(61.8/57.1)	(66.9/60.9)		 						1(1.0)		 	E4E4	0	0	NS	0	0/1	NS	 						(0/2.2)		 		13(17.6)	20(21.7)		18(23.7)	16(16.7)		 	E2E3	8/5	5/15	NS	9/9	6/10	NS	 		(20.0/14.7)	(12.5/28.8)		(26.4/21.4)	(12.0/21.7)		 		3(4.0)			3(3.9)	1(1.0)		 	E2E4	0/3	0	NS	0/3	1/0	NS	 		(0/8.9)			(0/7.2)	(2.0/0)		 		10(13.5)	16(17.4)		10(13.2)	16(16.7)		 	E3E4	7/3	8/8	NS	4/6	10/6	NS	 		(17.5/8.8)	(20.0/15.5)		(11.8/14.3)	(20.0/13.0)		 		16(10.8)	24(13.0)		21(13.8)	19(9.9)		 	E2	8/8	5/19	NS	9/12	7/12	NS	 		(10.0/11.8)	(6.3/18.3)		(13.2/14/3)	(7.0/13.0)		 		119(80.4)	144(78.3)		118(77.6)	154(80.2)		 	E3	65/54	67/77	NS	55/63	82/72	NS	 		(81.3/79.4)	(83.7/74.0)		(80.9/75.0)	(82.0/78.3)		 		13(8.8)	16(8.7)		13(8.6)	19(9.9)		 	E4	7/6	8/8	NS	4/9	11/8	NS	 		(8.7/8.8)	(10.0/7.7)		(5.9/10.7)	(11.0/8.7)		 		 	Total	148 (100)	184(100)		152(100)	192(100)		 	chromosomes	80/68	40/104		68/84	100/92		 		(54.1/45.9)	(43.5/56.5)		(44.7/55.3)	(52.1/47.9)		 	</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>9135</offset><text>NS, not significant (P value &gt; 0.05)</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>9172</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>9183</offset><text>Diabetic nephropathy and diabetic retinopathy are the two most important microangiopathic complications in Type I diabetic patients. Many of the environmental factors that influence the risk of vascular disease are known, but genetic components of the risk for diabetic microangiopathy are poorly understood. Several candidate genes have been investigated to elucidate the genetic factors responsible for vascular complications. The most important of these are the aldose reductase gene (ALR2), the insertion/deletion (I/D) polymorphism of the angiotensin I – converting enzyme (ACE) gene, C825T polymorphism of the gene encoding the beta-3 subunit of geterotrimeric G-proteins (GNB3), and C677T polymorphism of the methylenetetrahydrofolate reductase gene (MTHFR).</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>9951</offset><text>The genetic polymorphism of apolipoprotein E is associated with lipid abnormalities. Eto et al. suggested that lipid abnormalities may contribute to the development and progression of kidney disease, including diabetic nephropathy. The E2 allele frequency was significantly higher in Type II diabetes patients with nephropathy (7.2%) and with renal failure (9.7%) than in diabetic patients without nephropathy (2.6%). Apolipoprotein E polymorphism is associated with the progression of diabetic nephropathy. Presence of the apolipoprotein E4 allele is a protective factor, and other alleles entail risk factors.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>10563</offset><text>The genes responsible for genetic predisposition to vascular complications are still unknown, and little is known about the molecular basis of these complications. The influence of the APOE gene polymorphism to the development of diabetic microangiopathy is uncertain. Chowdhury et al. and Araki et al. demonstrated an association between the presence of the APOE E2 allele and diabetic nephropathy in Caucasian patients with Type I diabetes, although some investigators do not support this association.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>11067</offset><text>This study elucidated the role of APOE gene polymorphism in the predisposition to diabetic vascular complications. No association ofAPOE gene polymorphism with diabetic nephropathy was demonstrated. This result for diabetic nephropathy confirms the findings of Tarnow et al. and Onuma et al.. It should be mentioned that sample sizes in were larger than in this study. With increased sample size comes the possibility to demonstrate an association. But the larger the necessary and sufficient minimal sample size, the weaker the association demonstrated.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>11622</offset><text>We also analysed the association of the APOE gene polymorphism with diabetic retinopathy in the present study. No significant differences were found between groups with and without this vascular complication. A similar result has been shown by Tarnow et al. for diabetic retinopathy.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>11906</offset><text>Conclusions</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>11918</offset><text>The present study found no evidence for a role of the APOE gene polymorphism in genetic susceptibility for the development of diabetic retinopathy in Type I diabetes patients. Association between APOE gene polymorphism and diabetic nephropathy may be weak or moderate, but not strong.</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">title_1</infon><offset>12203</offset><text>COMPETING INTERESTS</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>12223</offset><text>None declared.</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>12238</offset><text>Pre-publication history</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">paragraph</infon><offset>12262</offset><text>The pre-publication history for this paper can be accessed here:</text></passage><passage><infon key="fpage">496</infon><infon key="lpage">501</infon><infon key="name_0">surname:Andersen;given-names:AR</infon><infon key="name_1">surname:Christiansen;given-names:JS</infon><infon key="name_2">surname:Andersen;given-names:JK</infon><infon key="name_3">surname:Kreiner;given-names:S</infon><infon key="name_4">surname:Deckert;given-names:T</infon><infon key="pub-id_pmid">6363177</infon><infon key="section_type">REF</infon><infon key="source">Diabetologia</infon><infon key="type">ref</infon><infon key="volume">25</infon><infon key="year">1983</infon><offset>12327</offset><text>Diabetic nephropathy in Type 1 (insulin dependent) diabetes: an epidemiological study</text></passage><passage><infon key="fpage">940</infon><infon key="lpage">945</infon><infon key="name_0">surname:Quinn;given-names:M</infon><infon key="name_1">surname:Angelico;given-names:MC</infon><infon key="name_2">surname:Warram;given-names:JH</infon><infon key="name_3">surname:Krolewski;given-names:AS</infon><infon key="pub-id_doi">10.1007/s001250050535</infon><infon key="pub-id_pmid">8858216</infon><infon key="section_type">REF</infon><infon key="source">Diabetologia</infon><infon key="type">ref</infon><infon key="volume">39</infon><infon key="year">1996</infon><offset>12413</offset><text>Familial factors determine the development of diabetic nephropathy in patients with IDDM</text></passage><passage><infon key="fpage">339</infon><infon key="lpage">347</infon><infon key="name_0">surname:Utermann;given-names:G</infon><infon key="name_1">surname:Langenbeck;given-names:U</infon><infon key="name_2">surname:Beisiegel;given-names:U</infon><infon key="name_3">surname:Weber;given-names:W</infon><infon key="pub-id_pmid">7386461</infon><infon key="section_type">REF</infon><infon key="source">Am J Hum Genet</infon><infon key="type">ref</infon><infon key="volume">32</infon><infon key="year">1980</infon><offset>12502</offset><text>Genetics of the apolipoprotein E system in man</text></passage><passage><infon key="fpage">1033</infon><infon key="lpage">1041</infon><infon key="name_0">surname:Zannis;given-names:VI</infon><infon key="name_1">surname:Breslow;given-names:JL</infon><infon key="pub-id_pmid">6260135</infon><infon key="section_type">REF</infon><infon key="source">Biochemistry</infon><infon key="type">ref</infon><infon key="volume">20</infon><infon key="year">1981</infon><offset>12549</offset><text>Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification</text></passage><passage><infon key="fpage">1155</infon><infon key="lpage">1166</infon><infon key="name_0">surname:Reilly;given-names:SL</infon><infon key="name_1">surname:Ferrell;given-names:RE</infon><infon key="name_2">surname:Kottke;given-names:BA</infon><infon key="name_3">surname:Kamboh;given-names:MI</infon><infon key="name_4">surname:Sing;given-names:CF</infon><infon key="pub-id_pmid">1842218</infon><infon key="section_type">REF</infon><infon key="source">Am J Hum Genet</infon><infon key="type">ref</infon><infon key="volume">49</infon><infon key="year">1991</infon><offset>12694</offset><text>The gender-specific apolipoprotein E genotype influence on the distribution of lipids and apolipoproteins in the population of Rochester, MN. I. Pleiotropic effects on means and variances</text></passage><passage><infon key="fpage">1100</infon><infon key="lpage">1110</infon><infon key="name_0">surname:Xhignesse;given-names:M</infon><infon key="name_1">surname:Lussier-Cacan;given-names:S</infon><infon key="name_2">surname:Sing;given-names:CF</infon><infon key="name_3">surname:Kessling;given-names:AM</infon><infon key="name_4">surname:Davignon;given-names:J</infon><infon key="pub-id_pmid">2065031</infon><infon key="section_type">REF</infon><infon key="source">Arterioscler Thromb</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">1991</infon><offset>12882</offset><text>Influences of common variants of apolipoprotein E on measures of lipid metabolism in a sample selected for health</text></passage><passage><infon key="fpage">439</infon><infon key="lpage">446</infon><infon key="name_0">surname:Bickeboller;given-names:H</infon><infon key="name_1">surname:Campion;given-names:D</infon><infon key="name_2">surname:Brice;given-names:A</infon><infon key="name_3">surname:Amouyel;given-names:P</infon><infon key="name_4">surname:Hannequin;given-names:D</infon><infon key="name_5">surname:Didierjean;given-names:0</infon><infon key="name_6">surname:Penet;given-names:C</infon><infon key="name_7">surname:Martin;given-names:C</infon><infon key="name_8">surname:Perez-Tur;given-names:J</infon><infon key="name_9">surname:Michon;given-names:A</infon><infon key="pub-id_pmid">9012418</infon><infon key="section_type">REF</infon><infon key="source">Am J Hum Genet</infon><infon key="type">ref</infon><infon key="volume">60</infon><infon key="year">1997</infon><offset>12996</offset><text>Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex</text></passage><passage><infon key="fpage">9</infon><infon key="lpage">15</infon><infon key="name_0">surname:Ukkola;given-names:0</infon><infon key="name_1">surname:Kervinen;given-names:K</infon><infon key="name_2">surname:Salmela;given-names:PI</infon><infon key="name_3">surname:von;given-names:DickhoffK</infon><infon key="name_4">surname:Laakso;given-names:M</infon><infon key="name_5">surname:Kesaniemi;given-names:YA</infon><infon key="pub-id_pmid">8216506</infon><infon key="section_type">REF</infon><infon key="source">Atherosclerosis</infon><infon key="type">ref</infon><infon key="volume">101</infon><infon key="year">1993</infon><offset>13075</offset><text>Apolipoprotein E phenotype is related to macro- and microangiopathy in patients with non-insulin-dependent diabetes mellitus</text></passage><passage><infon key="fpage">288</infon><infon key="lpage">292</infon><infon key="name_0">surname:Eto;given-names:M</infon><infon key="name_1">surname:Horita;given-names:K</infon><infon key="name_2">surname:Morikawa;given-names:A</infon><infon key="name_3">surname:Nakata;given-names:H</infon><infon key="name_4">surname:Okada;given-names:M</infon><infon key="name_5">surname:Saito;given-names:M</infon><infon key="name_6">surname:Nomura;given-names:M</infon><infon key="name_7">surname:Abiko;given-names:A</infon><infon key="name_8">surname:Iwashima;given-names:Y</infon><infon key="name_9">surname:Ikoda;given-names:A</infon><infon key="pub-id_pmid">8835322</infon><infon key="section_type">REF</infon><infon key="source">Clin Genet</infon><infon key="type">ref</infon><infon key="volume">48</infon><infon key="year">1995</infon><offset>13200</offset><text>Increased frequency of apolipoprotein epsilon 2 allele in non-insulin dependent diabetic (NIDDM) patients with nephropathy</text></passage><passage><infon key="fpage">278</infon><infon key="lpage">280</infon><infon key="name_0">surname:Chowdhury;given-names:TA</infon><infon key="name_1">surname:Dyer;given-names:PH</infon><infon key="name_2">surname:Kumar;given-names:S</infon><infon key="name_3">surname:Gibson;given-names:SP</infon><infon key="name_4">surname:Rowe;given-names:BR</infon><infon key="name_5">surname:Davies;given-names:SJ</infon><infon key="name_6">surname:Marshall;given-names:SM</infon><infon key="name_7">surname:Morris;given-names:PJ</infon><infon key="name_8">surname:Gill;given-names:GV</infon><infon key="name_9">surname:Feeney;given-names:S</infon><infon key="pub-id_pmid">9519726</infon><infon key="section_type">REF</infon><infon key="source">Diabetes</infon><infon key="type">ref</infon><infon key="volume">47</infon><infon key="year">1998</infon><offset>13323</offset><text>Association of apolipoprotein epsilon2 allele with diabetic nephropathy in Caucasian subjects with IDDM</text></passage><passage><infon key="fpage">2190</infon><infon key="lpage">2195</infon><infon key="name_0">surname:Araki;given-names:S</infon><infon key="name_1">surname:Moczulski;given-names:DK</infon><infon key="name_2">surname:Hanna;given-names:L</infon><infon key="name_3">surname:Scott;given-names:LJ</infon><infon key="name_4">surname:Warram;given-names:JH</infon><infon key="name_5">surname:Krolewski;given-names:AS</infon><infon key="pub-id_pmid">11118024</infon><infon key="section_type">REF</infon><infon key="source">Diabetes</infon><infon key="type">ref</infon><infon key="volume">49</infon><infon key="year">2000</infon><offset>13427</offset><text>APOE polymorphisms and the development of diabetic nephropathy in type 1 diabetes: results of case-control and family-based studies</text></passage><passage><infon key="section_type">REF</infon><infon key="source">WHO Technical Report Series 1985, 727 World Health Organization, Geneva</infon><infon key="type">ref</infon><offset>13559</offset><text>Diabetes Mellitus</text></passage><passage><infon key="fpage">1867</infon><infon key="lpage">1872</infon><infon key="name_0">surname:Jeppsson;given-names:JO</infon><infon key="name_1">surname:Jerntorp;given-names:P</infon><infon key="name_2">surname:Sundkvist;given-names:G</infon><infon key="name_3">surname:Englund;given-names:H</infon><infon key="name_4">surname:Nylund;given-names:V</infon><infon key="pub-id_pmid">3757206</infon><infon key="section_type">REF</infon><infon key="source">Clin Chem</infon><infon key="type">ref</infon><infon key="volume">32</infon><infon key="year">1986</infon><offset>13577</offset><text>Measurement of hemoglobin Alc by a new liquid-chromatographic assay: methodology, clinical utility, and relation to glucose tolerance evaluated</text></passage><passage><infon key="fpage">209</infon><infon key="lpage">213</infon><infon key="name_0">surname:Marre;given-names:M</infon><infon key="name_1">surname:Claudel;given-names:JP</infon><infon key="name_2">surname:Ciret;given-names:P</infon><infon key="name_3">surname:Luis;given-names:N</infon><infon key="name_4">surname:Suarez;given-names:L</infon><infon key="name_5">surname:Passa;given-names:P</infon><infon key="pub-id_pmid">3802503</infon><infon key="section_type">REF</infon><infon key="source">Clin Chem</infon><infon key="type">ref</infon><infon key="volume">33</infon><infon key="year">1987</infon><offset>13721</offset><text>Laser immunonephelometry for routine quantification of urinary albumin excretion</text></passage><passage><infon key="fpage">545</infon><infon key="lpage">548</infon><infon key="name_0">surname:Hixson;given-names:JE</infon><infon key="name_1">surname:Vernier;given-names:DT</infon><infon key="pub-id_pmid">2341813</infon><infon key="section_type">REF</infon><infon key="source">J Lipid Res</infon><infon key="type">ref</infon><infon key="volume">31</infon><infon key="year">1990</infon><offset>13802</offset><text>Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal</text></passage><passage><infon key="fpage">36</infon><infon key="lpage">40</infon><infon key="name_0">surname:Skobeleva;given-names:NA</infon><infon key="name_1">surname:Vasina;given-names:VI</infon><infon key="name_2">surname:Volkova;given-names:MV</infon><infon key="name_3">surname:Sverdlova;given-names:AM</infon><infon key="name_4">surname:Fomicheva;given-names:EV</infon><infon key="name_5">surname:Obraztsova;given-names:GI</infon><infon key="name_6">surname:Talalaeva;given-names:El</infon><infon key="name_7">surname:Shakir;given-names:K</infon><infon key="name_8">surname:Laasri;given-names:M</infon><infon key="name_9">surname:Vorontsov;given-names:IM</infon><infon key="pub-id_pmid">9411220</infon><infon key="section_type">REF</infon><infon key="source">Mol Gen Mikrobiol Virusol</infon><infon key="type">ref</infon><infon key="volume">4</infon><infon key="year">1997</infon><offset>13895</offset><text>DNA polymorphism of the APOB100, APOCIII, APOE, and angiotensin-converting enzyme genes and indicators of the lipid spectrum in children and adolescents in St. Petersburg</text></passage><passage><infon key="fpage">287</infon><infon key="lpage">291</infon><infon key="name_0">surname:Heesom;given-names:AE</infon><infon key="name_1">surname:Hibberd;given-names:ML</infon><infon key="name_2">surname:Millward;given-names:A</infon><infon key="name_3">surname:Demaine;given-names:AG</infon><infon key="pub-id_pmid">9000706</infon><infon key="section_type">REF</infon><infon key="source">Diabetes</infon><infon key="type">ref</infon><infon key="volume">46</infon><infon key="year">1997</infon><offset>14066</offset><text>Polymorphism in the 5'-end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type I diabetes</text></passage><passage><infon key="fpage">690</infon><infon key="lpage">695</infon><infon key="name_0">surname:Doria;given-names:A</infon><infon key="name_1">surname:Warram;given-names:JH</infon><infon key="name_2">surname:Krolewski;given-names:AS</infon><infon key="pub-id_pmid">7909524</infon><infon key="section_type">REF</infon><infon key="source">Diabetes</infon><infon key="type">ref</infon><infon key="volume">43</infon><infon key="year">1994</infon><offset>14209</offset><text>Genetic predisposition to diabetic nephropathy. Evidence for a role of the angiotensin I – converting enzyme gene</text></passage><passage><infon key="fpage">S28</infon><infon key="lpage">S32</infon><infon key="name_0">surname:Ha;given-names:SK</infon><infon key="name_1">surname:Seo;given-names:JK</infon><infon key="pub-id_pmid">9285899</infon><infon key="section_type">REF</infon><infon key="source">Kidney Int Suppl</infon><infon key="type">ref</infon><infon key="volume">60</infon><infon key="year">1997</infon><offset>14325</offset><text>Insertion/deletion polymorphism in ACE gene as a predictor for progression of diabetic nephropathy</text></passage><passage><infon key="fpage">1304</infon><infon key="lpage">1308</infon><infon key="name_0">surname:Fogarty;given-names:DG</infon><infon key="name_1">surname:Zychma;given-names:MJ</infon><infon key="name_2">surname:Scott;given-names:LJ</infon><infon key="name_3">surname:Warram;given-names:JH</infon><infon key="name_4">surname:Krolewski;given-names:AS</infon><infon key="pub-id_doi">10.1007/s001250051069</infon><infon key="pub-id_pmid">9833937</infon><infon key="section_type">REF</infon><infon key="source">Diabetologia</infon><infon key="type">ref</infon><infon key="volume">41</infon><infon key="year">1998</infon><offset>14424</offset><text>The C825T polymorphism in the human G-protein beta3 subunit gene is not associated with diabetic nephropathy in Type I diabetes mellitus</text></passage><passage><infon key="fpage">1298</infon><infon key="lpage">1306</infon><infon key="name_0">surname:Siffert;given-names:W</infon><infon key="pub-id_doi">10.1093/ndt/15.9.1298</infon><infon key="pub-id_pmid">10978382</infon><infon key="section_type">REF</infon><infon key="source">Nephrol Dial Transplant</infon><infon key="type">ref</infon><infon key="volume">15</infon><infon key="year">2000</infon><offset>14561</offset><text>G protein beta3 subunit 825T allele, hypertension, obesity, and diabetic nephropathy</text></passage><passage><infon key="fpage">188</infon><infon key="lpage">191</infon><infon key="name_0">surname:Shcherbak;given-names:NS</infon><infon key="name_1">surname:Schwartz;given-names:El</infon><infon key="pub-id_doi">10.1007/s100380170087</infon><infon key="pub-id_pmid">11322658</infon><infon key="section_type">REF</infon><infon key="source">Journal of Human Genetics</infon><infon key="type">ref</infon><infon key="volume">46</infon><infon key="year">2001</infon><offset>14646</offset><text>The C825T polymorphism in the G-protein β3 subunit gene and diabetic complications in IDDM patients</text></passage><passage><infon key="fpage">375</infon><infon key="lpage">378</infon><infon key="name_0">surname:Shcherbak;given-names:NS</infon><infon key="name_1">surname:Shutskaya;given-names:ZhV</infon><infon key="name_2">surname:Sheidina;given-names:AM</infon><infon key="name_3">surname:Larionova;given-names:VI</infon><infon key="name_4">surname:Schwartz;given-names:El</infon><infon key="pub-id_doi">10.1006/mgme.1999.2909</infon><infon key="pub-id_pmid">10562465</infon><infon key="section_type">REF</infon><infon key="source">Molecular Genetics and Metabolism</infon><infon key="type">ref</infon><infon key="volume">68</infon><infon key="year">1999</infon><offset>14749</offset><text>Methylenetetrahydrofolate Reductase Gene Polymorphism as a Risk Factor for Diabetic Nephropathy in IDDM Patients</text></passage><passage><infon key="fpage">666</infon><infon key="lpage">673</infon><infon key="name_0">surname:Kimura;given-names:H</infon><infon key="name_1">surname:Suzuki;given-names:Y</infon><infon key="name_2">surname:Gejyo;given-names:F</infon><infon key="name_3">surname:Karasawa;given-names:R</infon><infon key="name_4">surname:Miyazaki;given-names:R</infon><infon key="name_5">surname:Suzuki;given-names:S</infon><infon key="name_6">surname:Arakawa;given-names:M</infon><infon key="pub-id_pmid">9531184</infon><infon key="section_type">REF</infon><infon key="source">Am J Kidney Dis</infon><infon key="type">ref</infon><infon key="volume">31</infon><infon key="year">1998</infon><offset>14862</offset><text>Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM</text></passage><passage><infon key="fpage">625</infon><infon key="lpage">630</infon><infon key="name_0">surname:Tamow;given-names:L</infon><infon key="name_1">surname:Stehouwer;given-names:CD</infon><infon key="name_2">surname:Emeis;given-names:JJ</infon><infon key="name_3">surname:Poirier;given-names:0</infon><infon key="name_4">surname:Cambien;given-names:F</infon><infon key="name_5">surname:Hansen;given-names:BV</infon><infon key="pub-id_doi">10.1093/ndt/15.5.625</infon><infon key="pub-id_pmid">10809802</infon><infon key="section_type">REF</infon><infon key="source">Nephrol Dial Transplant</infon><infon key="type">ref</infon><infon key="volume">15</infon><infon key="year">2000</infon><offset>14940</offset><text>Parving HH: Plasminogen activator inhibitor-1 and apolipoprotein E gene polymorphisms and diabetic angiopathy</text></passage><passage><infon key="fpage">1075</infon><infon key="lpage">1078</infon><infon key="name_0">surname:Onuma;given-names:T</infon><infon key="name_1">surname:Laffel;given-names:LM</infon><infon key="name_2">surname:Angelico;given-names:MC</infon><infon key="name_3">surname:Krolewski;given-names:AS</infon><infon key="pub-id_pmid">8829124</infon><infon key="section_type">REF</infon><infon key="source">J Am Soc Nephrol</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">1996</infon><offset>15050</offset><text>Apolipoprotein E genotypes and risk of diabetic nephropathy</text></passage></document></collection>
